Dossier assessment
Nintedanib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)
Report documents
-
Dossier assessment
Nintedanib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)
Project details
- Project no.
- G15-03
- Commission
- Commission awarded on 15.03.2015 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Health Economics
- Topic
- Airways and respiratory system
- Note
-
In accordance with § 35a (para. 1, sentence 10) Social Code Book V, the added medical benefit of orphan drugs is deemed as proven by the fact that they have been approved. For the Nintedanib report commissioned by the Federal Joint Committee (G-BA), IQWiG therefore solely assesses the information on patient numbers and costs in the pharmaceutical company's dossier.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. The resolution on the extent of added benefit is passed by the G-BA after the hearing. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA Website.
Connected Projects
-
Dossier assessment
Nintedanib (idiopathic pulmonary fibrosis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nintedanib - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Status: Commission completed
-
Dossier assessment
Nintedanib (fibrosing interstitial lung diseases, 6 to < 18 years) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nintedanib (systemic sclerosis associated interstitial lung disease, 6 to < 18 years) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nintedanib (systemic sclerosis associated interstitial lung disease in adults) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Nintedanib (interstitial lung disease) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed